The extended human leukocyte receptor complex: Diverse ways of modulating immune responses

Immunological Reviews

Volumn 224, Issue 1, 2008, Pages 98-123

  Barrow, Alexander David ^a   Trowsdale, John ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Adapters; ITAM; ITIM; KIR; LILR; SIGLEC

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CARRIER PROTEINS AND BINDING PROTEINS; CD79A ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN RECEPTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; LECTIN; LEUKOCYTE RECEPTOR COMPLEX; LYMPHOCYTE ANTIGEN; PROTEIN DAP10; PROTEIN NCR; RECEPTOR PROTEIN; SIALIC ACID;

CHROMOSOME 19; GENE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LAIR 1 GENE; LAIR 2 GENE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CHROMOSOMES, HUMAN, PAIR 19; FEEDBACK, BIOCHEMICAL; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MODELS, IMMUNOLOGICAL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 49249119291     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00653.x     Document Type: Review

References (273)

1. Humphrey MB, Lanier LL, Nakamura MC. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev 2005 208 : 50 65.
2. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000 290 : 84 89.
3. Wilson MJ, et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA 2000 97 : 4778 4783.
4. Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002 190 : 40 52.
5. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005 5 : 201 214.
6. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002 20 : 217 251.
7. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA 1993 90 : 12000 12004.
8. Canavez F, et al. Comparison of chimpanzee and human leukocyte Ig-like receptor genes reveals framework and rapidly evolving genes. J Immunol 2001 167 : 5786 5794.
9. Guethlein LA, Flodin LR, Adams EJ, Parham P. NK cell receptors of the orangutan (Pongo pygmaeus): a pivotal species for tracking the coevolution of killer cell Ig-like receptors with MHC-C. J Immunol 2002 169 : 220 229.
10. Khakoo SI, et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 2000 12 : 687 698.
11. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 2002 38 : 1007 1021.
12. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994 180 : 1235 1242.
13. Uhrberg M, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997 7 : 753 763.
14. Sambrook JG, et al. Identification of the ancestral killer immunoglobulin-like receptor gene in primates. BMC Genomics 2006 7 : 209.
15. Lanier LL, Phillips JH. NK cell recognition of major histocompatibility complex class I molecules. Semin Immunol 1995 7 : 75 82.
16. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006 18 : 151 158.
17. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006 214 : 155 160.
18. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006 214 : 143 154.
19. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006 203 : 633 645.
20. Thananchai H, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007 178 : 33 37.
21. Hansasuta P, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 2004 34 : 1673 1679.
22. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005 102 : 13224 13229.
23. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001 167 : 5543 5547.
24. Vales-Gomez M, Reyburn HT, Erskine RA, Strominger J. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci USA 1998 95 : 14326 14331.
25. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev 2006 214 : 186 201.
26. Barten R, Torkar M, Haude A, Trowsdale J, Wilson MJ. Divergent and convergent evolution of NK-cell receptors. Trends Immunol 2001 22 : 52 57.
27. Wende H, Volz A, Ziegler A. Extensive gene duplications and a large inversion characterize the human leukocyte receptor cluster. Immunogenetics 2000 51 : 703 713.
28. Cao W, et al. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 2006 203 : 1399 1405.
29. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005 23 : 275 306.
30. Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004 64 : 215 225.
31. Katz HR. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev 2007 217 : 222 230.
32. Gonen-Gross T, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003 171 : 1343 1351.
33. Shiroishi M, et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d) . Proc Natl Acad Sci USA 2006 103 : 16412 16417.
34. Cosman D, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997 7 : 273 282.
35. Suciu-Foca N, et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 2007 178 : 7432 7441.
36. Gruda R, et al. Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1. J Immunol 2007 179 : 3655 3661.
37. Harari A, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007 104 : 16233 16238.
38. Lichterfield M, et al. A viral CTL scape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med 2007 204 : 2813 2824.
39. Cerboni C, et al. Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol 2006 36 : 732 741.
40. Sayos J, Martinez-Barriocanal A, Kitzig F, Bellon T, Lopez-Botet M. Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. Biochem Biophys Res Commun 2004 324 : 640 647.
41. Chang CC, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002 3 : 237 243.
42. Nakamura A, Kobayashi E, Takai T. Exacerbated graft-versus-host disease in Pirb-/- mice. Nat Immunol 2004 5 : 623 629.
43. Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T. Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(-/-) mice. Nat Immunol 2002 3 : 542 548.
44. Liang S, Baibakov B, Horuzsko A. HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. Eur J Immunol 2002 32 : 2418 2426.
45. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005 35 : 1133 1142.
46. Colonna M, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997 186 : 1809 1818.
47. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol 1998 28 : 3423 3434.
48. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol 1999 162 : 5 8.
49. Tenca C, et al. CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. J Immunol 2005 174 : 6757 6763.
50. Young NT, Waller EC, Patel R, Roghanian A, Austyn JM, Trowsdale J. The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. Blood 2008 111 : 3090 3096.
51. Wagner CS, Walther-Jallow L, Buentke E, Ljunggren HG, Achour A, Chambers BJ. Human cytomegalovirus-derived protein UL18 alters the phenotype and function of monocyte-derived dendritic cells. J Leukoc Biol 2008 83 : 56 63.
52. Kim-Schulze S, et al. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+T suppressor cells. J Immunol 2006 176 : 2790 2798.
53. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 2007 248 : 59 67.
54. Lee DJ, et al. LILRA2 Activation Inhibits Dendritic Cell Differentiation and Antigen Presentation to T Cells. J Immunol 2007 179 : 8128 8136.
55. Koch S, et al. Association of multiple sclerosis with ILT6 deficiency. Genes Immun 2005 6 : 445 447.
56. Kuroki K, et al. Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis. Hum Mol Genet 2005 14 : 2469 2480.
57. Hirayasu K, et al. Long-term persistence of both functional and non-functional alleles at the leukocyte immunoglobulin-like receptor A3 (LILRA3) locus suggests balancing selection. Hum Genet 2006 119 : 436 443.
58. Meyaard L, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997 7 : 283 290.
59. Lebbink RJ, de Ruiter T, Kaptijn GJ, Meyaard L. Identification and characterization of the rat homologue of LAIR-1. Immunogenetics 2005 57 : 344 351.
60. Lebbink RJ, de Ruiter T, Verbrugge A, Bril WS, Meyaard L. The mouse homologue of the leukocyte-associated Ig-like receptor-1 is an inhibitory receptor that recruits Src homology region 2-containing protein tyrosine phosphatase (SHP)-2, but not SHP-1. J Immunol 2004 172 : 5535 5543.
61. Poggi A, et al. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol 1995 25 : 369 376.
62. Poggi A, Tomasello E, Revello V, Nanni L, Costa P, Moretta L. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Int Immunol 1997 9 : 1271 1279.
63. Poggi A, Tomasello E, Ferrero E, Zocchi MR, Moretta L. p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol 1998 28 : 2086 2091.
64. Verbrugge A, de Ruiter T, Geest C, Coffer PJ, Meyaard L. Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation. J Leukoc Biol 2006 79 : 828 836.
65. Florian S, et al. Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy 2006 61 : 1054 1062.
66. Ouyang W, et al. 9.1C3 is identical to LAIR-1, which is expressed on hematopoietic progenitors. Biochem Biophys Res Commun 2003 310 : 1236 1240.
67. Maasho K, Masilamani M, Valas R, Basu S, Coligan JE, Borrego F. The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation. Mol Immunol 2005 42 : 1521 1530.
68. Meyaard L, Hurenkamp J, Clevers H, Lanier LL, Phillips JH. Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. J Immunol 1999 162 : 5800 5804.
69. Fournier N, et al. FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells. J Immunol 2000 165 : 1197 1209.
70. van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling. Eur J Immunol 1999 29 : 3160 3167.
71. Verbrugge A, Ruiter Td T, Clevers H, Meyaard L. Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment. Int Immunol 2003 15 : 1349 1358.
72. Zocchi MR, Pellegatta F, Pierri I, Gobbi M, Poggi A. Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells. Eur J Immunol 2001 31 : 3667 3675.
73. Poggi A, Pellegatta F, Leone BE, Moretta L, Zocchi MR. Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol 2000 30 : 2751 2758.
74. Xu M, Zhao R, Zhao ZJ. Identification and characterization of leukocyte-associated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cells. J Biol Chem 2000 275 : 17440 17446.
75. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998 92 : 441 450.
76. Sathish JG, et al. Constitutive association of SHP-1 with leukocyte-associated Ig-like receptor-1 in human T cells. J Immunol 2001 166 : 1763 1770.
77. Verbrugge A, Rijkers ES, de Ruiter T, Meyaard L. Leukocyte-associated Ig-like receptor-1 has SH2 domain-containing phosphatase-independent function and recruits C-terminal Src kinase. Eur J Immunol 2006 36 : 190 198.
78. Imamoto A, Soriano P. Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell 1993 73 : 1117 1124.
79. Nada S, et al. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 1993 73 : 1125 1135.
80. Veillette A, Thibaudeau E, Latour S. High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J Biol Chem 1998 273 : 22719 22728.
81. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008 83 : 799 803.
82. Lebbink RJ, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med 2006 203 : 1419 1425.
83. Jandrot-Perrus M, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000 96 : 1798 1807.
84. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989 84 : 1440 1445.
85. Tomlinson MG, et al. Collagen promotes sustained glycoprotein VI signaling in platelets and cell lines. J Thromb Haemost 2007 5 : 2274 2283.
86. Lebbink RJ, et al. Mouse leukocyte-associated Ig-like receptor-1 (mLAIR-1) functions as an inhibitory collagen-binding receptor on immune cells. Int Immunol 2007 19 : 1011 1019.
87. Ouyang W, et al. Establishment of an ELISA system for determining soluble LAIR-1 levels in sera of patients with HFRS and kidney transplant. J Immunol Methods 2004 292 : 109 117.
88. Kremer EJ, Kalatzis V, Baker E, Callen DF, Sutherland GR, Maliszewski CR. The gene for the human IgA Fc receptor maps to 19q13.4. Hum Genet 1992 89 : 107 108.
89. Ding Y, et al. Crystal structure of the ectodomain of human FcalphaRI. J Biol Chem 2003 278 : 27966 27970.
90. Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature 2003 423 : 614 620.
91. Pfefferkorn LC, Yeaman GR. Association of IgA-Fc receptors (Fc alpha R) with Fc epsilon RI gamma 2 subunits in U937 cells. Aggregation induces the tyrosine phosphorylation of gamma 2. J Immunol 1994 153 : 3228 3236.
92. Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC. Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem 1999 274 : 7216 7225.
93. Maliszewski CR, March CJ, Schoenborn MA, Gimpel S, Shen L. Expression cloning of a human Fc receptor for IgA. J Exp Med 1990 172 : 1665 1672.
94. Zhang G, Young JR, Tregaskes CA, Sopp P, Howard CJ. Identification of a novel class of mammalian Fc gamma receptor. J Immunol 1995 155 : 1534 1541.
95. Geissmann F, et al. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J Immunol 2001 166 : 346 352.
96. Heystek HC, Moulon C, Woltman AM, Garonne P, van Kooten C. Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation. J Immunol 2002 168 : 102 107.
97. Monteiro RC, Kubagawa H, Cooper MD. Cellular distribution, regulation, and biochemical nature of an Fc alpha receptor in humans. J Exp Med 1990 171 : 597 613.
98. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003 21 : 177 204.
99. Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol 1996 16 : 423 440.
100. van Egmond M, et al. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000 6 : 680 685.
101. Hamre R, Farstad IN, Brandtzaeg P, Morton HC. Expression and modulation of the human immunoglobulin A Fc receptor (CD89) and the FcR gamma chain on myeloid cells in blood and tissue. Scand J Immunol 2003 57 : 506 516.
102. Grossetete B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int 1998 53 : 1321 1335.
103. Yoo EM, Morrison SL. IgA: an immune glycoprotein. Clin Immunol 2005 116 : 3 10.
104. Otten MA, van Egmond M. The Fc receptor for IgA (FcalphaRI, CD89). Immunol Lett 2004 92 : 23 31.
105. Wines BD, Hulett MD, Jamieson GP, Trist HM, Spratt JM, Hogarth PM. Identification of residues in the first domain of human Fc alpha receptor essential for interaction with IgA. J Immunol 1999 162 : 2146 2153.
106. Carayannopoulos L, Hexham JM, Capra JD. Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med 1996 183 : 1579 1586.
107. Pleass RJ, Dunlop JI, Anderson CM, Woof JM. Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89. J Biol Chem 1999 274 : 23508 23514.
108. van Egmond M, Damen CA, van Spriel AB, Vidarsson G, van Garderen E, van de Winkel JG. IgA and the IgA Fc receptor. Trends Immunol 2001 22 : 205 211.
109. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001 19 : 275 290.
110. Pasquier B, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005 22 : 31 42.
111. Kanamaru Y, Blank U, Monteiro RC. IgA Fc receptor I is a molecular switch that determines IgA activating or inhibitory functions. Contrib Nephrol 2007 157 : 148 152.
112. Kanamaru Y, et al. IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth. Blood 2007 109 : 203 211.
113. Moretta A, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001 19 : 197 223.
114. Pessino A, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998 188 : 953 960.
115. Mandelboim O, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001 409 : 1055 1060.
116. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002 195 : 343 351.
117. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002 195 : 327 333.
118. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002 195 : 335 341.
119. Spaggiari GM, et al. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol 2001 31 : 1656 1665.
120. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002 2 : 957 964.
121. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006 6 : 433 446.
122. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006 18 : 565 571.
123. Stern-Ginossar N, et al. Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells. J Immunol 2007 179 : 4424 4434.
124. Motran CC, Diaz FL, Gruppi A, Slavin D, Chatton B, Bocco JL. Human pregnancy-specific glycoprotein 1a (PSG1a) induces alternative activation in human and mouse monocytes and suppresses the accessory cell-dependent T cell proliferation. J Leukoc Biol 2002 72 : 512 521.
125. Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 1991 6 : 691 704.
126. Nagata K, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996 271 : 30022 30027.
127. Stitt TN, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995 80 : 661 670.
128. Varnum BC, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995 373 : 623 626.
129. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene 1995 10 : 2349 2359.
130. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994 5 : 647 657.
131. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001 293 : 306 311.
132. Caraux A, et al. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol 2006 7 : 747 754.
133. Camenisch TD, Koller BH, Earp HS, Matsushima GK. A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide- induced endotoxic shock. J Immunol 1999 162 : 3498 3503.
134. Cohen PL, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002 196 : 135 140.
135. Scott RS, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001 411 : 207 211.
136. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007 131 : 1124 1136.
137. Kraus M, Saijo K, Torres RM, Rajewsky K. Ig-alpha cytoplasmic truncation renders immature B cells more sensitive to antigen contact. Immunity 1999 11 : 537 545.
138. Torres RM, Hafen K. A negative regulatory role for Ig-alpha during B cell development. Immunity 1999 11 : 527 536.
139. Reichlin A, et al. A B cell receptor with two Igalpha cytoplasmic domains supports development of mature but anergic B cells. J Exp Med 2004 199 : 855 865.
140. Muller R, Wienands J, Reth M. The serine and threonine residues in the Ig-alpha cytoplasmic tail negatively regulate immunoreceptor tyrosine-based activation motif-mediated signal transduction. Proc Natl Acad Sci USA 2000 97 : 8451 8454.
141. Pracht C, Minguet S, Leitges M, Reth M, Huber M. Association of protein kinase C-delta with the B cell antigen receptor complex. Cell Signal 2007 19 : 715 722.
142. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 1989 337 : 184 187.
143. Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol 1985 15 : 733 738.
144. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 1972 51 : 2916 2927.
145. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 1996 157 : 3317 3322.
146. Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol 1996 26 : 1527 1531.
147. Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 1994 372 : 336 343.
148. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994 372 : 379 383.
149. Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001 7 : 867 877.
150. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol 1976 71 : 666 669.
151. Israel EJ, Patel VK, Taylor SF, Marshak-Rothstein A, Simister NE. Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol 1995 154 : 6246 6251.
152. Roopenian DC, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003 170 : 3528 3533.
153. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996 26 : 690 696.
154. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996 93 : 5512 5516.
155. Spriggs MK, et al. Beta 2-microglobulin-, CD8+T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci USA 1992 89 : 6070 6074.
156. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007 7 : 715 725.
157. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002 81 : 203 206.
158. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: structure, regulation, and clinical implications. Neurobiol Dis 2004 16 : 1 13.
159. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001 114 : 168 172.
160. Deane R, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005 25 : 11495 11503.
161. Haymann JP, et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 2000 11 : 632 639.
162. Kobayashi N, Suzuki Y, Tsuge T, Okumura K, Ra C, Tomino Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 2002 282 : F358 F365.
163. Akilesh S, et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 2008 105 : 967 972.
164. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004 113 : 1328 1333.
165. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002 88 : 898 899.
166. Li N, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005 115 : 3440 3450.
167. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999 340 : 227 228.
168. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature 1964 203 : 1352 1354.
169. Humphrey JH, Fahey JL. The metabolism of normal plasma proteins and gamma-myeloma protein in mice bearing plasma-cell tumors. J Clin Invest 1961 40 : 1696 1705.
170. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007 7 : 255 266.
171. Angata T, Margulies EH, Green ED, Varki A. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc Natl Acad Sci USA 2004 101 : 13251 13256.
172. Klein J, O'HUigin C. Composite origin of major histocompatibility complex genes. Curr Opin Genet Dev 1993 3 : 923 930.
173. Klein J, Sato A, O'HUigin C. Evolution by gene duplication in the major histocompatibility complex. Cytogenet Cell Genet 1998 80 : 123 127.
174. Bakker TR, Piperi C, Davies EA, Merwe PA. Comparison of CD22 binding to native CD45 and synthetic oligosaccharide. Eur J Immunol 2002 32 : 1924 1932.
175. Blixt O, Collins BE, van den Nieuwenhof IM, Crocker PR, Paulson JC. Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J Biol Chem 2003 278 : 31007 31019.
176. Kelm S, Schauer R, Manuguerra JC, Gross HJ, Crocker PR. Modifications of cell surface sialic acids modulate cell adhesion mediated by sialoadhesin and CD22. Glycoconj J 1994 11 : 576 585.
177. Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem 1993 268 : 7019 7027.
178. Hayakawa T, Angata T, Lewis AL, Mikkelsen TS, Varki NM, Varki A. A human-specific gene in microglia. Science 2005 309 : 1693.
179. Yamaji T, Teranishi T, Alphey MS, Crocker PR, Hashimoto Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J Biol Chem 2002 277 : 6324 6332.
180. Bochner BS, et al. Glycan array screening reveals a candidate ligand for Siglec-8. J Biol Chem 2005 280 : 4307 4312.
181. Campanero-Rhodes MA, et al. Carbohydrate microarrays reveal sulphation as a modulator of siglec binding. Biochem Biophys Res Commun 2006 344 : 1141 1146.
182. Tateno H, Crocker PR, Paulson JC. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6′-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 2005 15 : 1125 1135.
183. Alphey MS, Attrill H, Crocker PR, van Aalten DM. High-resolution crystal structures of Siglec-7. Insights into ligand specificity in the Siglec family. J Biol Chem 2003 278 : 3372 3377.
184. Attrill H, Imamura A, Sharma RS, Kiso M, Crocker PR, van Aalten DM. Siglec-7 undergoes a major conformational change when complexed with the alpha(2,8)-disialylganglioside GT1b. J Biol Chem 2006 281 : 32774 32783.
185. Attrill H, et al. The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem J 2006 397 : 271 278.
186. May AP, Robinson RC, Vinson M, Crocker PR, Jones EY. Crystal structure of the N-terminal domain of sialoadhesin in complex with 3′ sialyllactose at 1.85 A resolution. Mol Cell 1998 1 : 719 728.
187. Zaccai NR, et al. Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure 2003 11 : 557 567.
188. Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends
189. Angata T, Kerr SC, Greaves DR, Varki NM, Crocker PR, Varki A. Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem 2002 277 : 24466 24474.
190. Kitzig F, Martinez-Barriocanal A, Lopez-Botet M, Sayos J. Cloning of two new splice variants of Siglec-10 and mapping of the interaction between Siglec-10 and SHP-1. Biochem Biophys Res Commun 2002 296 : 355 362.
191. Ulyanova T, Shah DD, Thomas ML. Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2. J Biol Chem 2001 276 : 14451 14458.
192. Whitney G, et al. A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. Eur J Biochem 2001 268 : 6083 6096.
193. Yamaji T, Mitsuki M, Teranishi T, Hashimoto Y. Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs. Glycobiology 2005 15 : 667 676.
194. Yu Z, Lai CM, Maoui M, Banville D, Shen SH. Identification and characterization of S2 V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs. J Biol Chem 2001 276 : 23816 23824.
195. Walker JA, Smith KG. CD22: an inhibitory enigma. Immunology 2008 123 : 314 325.
196. Doody GM, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 1995 269 : 242 244.
197. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity 1999 11 : 191 200.
198. Gerlach J, et al. B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling. Eur J Immunol 2003 33 : 3418 3426.
199. Sato S, Jansen PJ, Tedder TF. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc Natl Acad Sci USA 1997 94 : 13158 13162.
200. Nitschke L, Carsetti R, Ocker B, Kohler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997 7 : 133 143.
201. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996 274 : 798 801.
202. Otipoby KL, et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 1996 384 : 634 637.
203. Poe JC, Haas KM, Uchida J, Lee Y, Fujimoto M, Tedder TF. Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc: Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. J Immunol 2004 172 : 2100 2110.
204. Hennet T, Chui D, Paulson JC, Marth JD. Immune regulation by the ST6Gal sialyltransferase. Proc Natl Acad Sci USA 1998 95 : 4504 4509.
205. Collins BE, Smith BA, Bengtson P, Paulson JC. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol 2006 7 : 199 206.
206. Law CL, et al. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J Exp Med 1996 183 : 547 560.
207. Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem 2000 275 : 17420 17427.
208. Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH. Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. Eur J Immunol 1996 26 : 1246 1252.
209. Wienands J, Freuler F, Baumann G. Tyrosine-phosphorylated forms of Ig beta, CD22, TCR zeta and HOSS are major ligands for tandem SH2 domains of Syk. Int Immunol 1995 7 : 1701 1708.
210. Balaian L, Ball ED. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk Res 2004 28 : 821 829.
211. Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem 2004 279 : 43117 43125.
212. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA 2006 103 : 7765 7770.
213. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000 96 : 483 490.
214. Vitale C, et al. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci USA 1999 96 : 15091 15096.
215. Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003 101 : 5014 5020.
216. von Gunten S, et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 2005 106 : 1423 1431.
217. Orr SJ, et al. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem 2007 282 : 3418 3422.
218. Orr SJ, et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 2007 109 : 1061 1068.
219. Blasius AL, Cella M, Maldonado J, Takai T, Colonna M. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006 107 : 2474 2476.
220. Zhang J, et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 2006 107 : 3600 3608.
221. Blasius AL, Colonna M. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol 2006 27 : 255 260.
222. Colonna M, Cella M. Crosspresentation: plasmacytoid dendritic cells are in the business. Immunity 2007 27 : 419 421.
223. Angata T, Hayakawa T, Yamanaka M, Varki A, Nakamura M. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J 2006 20 : 1964 1973.
224. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999 285 : 727 729.
225. Cella M, et al. Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity. J Exp Med 2004 200 : 817 823.
226. Chang C, et al. Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J Immunol 1999 163 : 4651 4654.
227. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 2006 7 : 524 532.
228. Wu J, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999 285 : 730 732.
229. Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 2005 102 : 7641 7646.
230. Cerwenka A, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000 12 : 721 727.
231. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000 1 : 119 126.
232. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007 7 : 737 744.
233. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005 436 : 1186 1190.
234. Diefenbach A, et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002 3 : 1142 1149.
235. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002 3 : 1150 1155.
236. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007 8 : 1345 1352.
237. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002 419 : 734 738.
238. Kaiser BK, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007 447 : 482 486.
239. Ogasawara K, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004 20 : 757 767.
240. Osaki T, et al. Decreased NKG2D expression on CD8+T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 2007 13 : 382 387.
241. Raffaghello L, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004 6 : 558 568.
242. Wiemann K, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005 175 : 720 729.
243. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004 114 : 560 568.
244. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 2008 111 : 3571 3578.
245. Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005 34 : 206 213.
246. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006 7 : 755 762.
247. Hyka-Nouspikel N, Lucian L, Murphy E, McClanahan T, Phillips JH. DAP10 deficiency breaks the immune tolerance against transplantable syngeneic melanoma. J Immunol 2007 179 : 3763 3771.
248. Hyka-Nouspikel N, Phillips JH. Physiological roles of murine DAP10 adapter protein in tumor immunity and autoimmunity. Immunol Rev 2006 214 : 106 117.
249. Hayday A, Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. Nat Rev Immunol 2003 3 : 233 242.
250. Nanno M, Shiohara T, Yamamoto H, Kawakami K, Ishikawa H. gammadelta T cells: firefighters or fire boosters in the front lines of inflammatory responses. Immunol Rev 2007 215 : 103 113.
251. Wu H, Knight JF, Alexander SI. Regulatory gamma delta T cells in Heymann nephritis express an invariant Vgamma6/Vdelta1 with a canonical CDR3 sequence. Eur J Immunol 2004 34 : 2322 2330.
252. Wu H, et al. Depletion of gammadelta T cells exacerbates murine adriamycin nephropathy. J Am Soc Nephrol 2007 18 : 1180 1189.
253. Rabinovich BA, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol 2003 170 : 3572 3576.
254. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007 110 : 606 615.
255. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998 391 : 703 707.
256. Tomasello E, et al. Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor-associated protein (KARAP)/DAP-12. J Biol Chem 1998 273 : 34115 34119.
257. McVicar DW, Burshtyn DN. Intracellular signaling by the killer immunoglobulin-like receptors and Ly49. Sci STKE 2001 75 : RE1.
258. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000 164 : 4991 4995.
259. Dietrich J, Cella M, Seiffert M, Buhring HJ, Colonna M. Cutting edge: signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells. J Immunol 2000 164 : 9 12.
260. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998 8 : 693 701.
261. Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 1998 161 : 7 10.
262. Colonna M. DAP12 signaling: from immune cells to bone modeling and brain myelination. J Clin Invest 2003 111 : 313 314.
263. Hamerman JA, Tchao NK, Lowell CA, Lanier LL. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 2005 6 : 579 586.
264. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001 410 : 1103 1107.
265. Turnbull IR, McDunn JE, Takai T, Townsend RR, Cobb JP, Colonna M. DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. J Exp Med 2005 202 : 363 369.
266. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 2006 177 : 2051 2055.
267. Turnbull IR, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 2006 177 : 3520 3524.
268. Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 2005 106 : 2076 2082.
269. Hamerman JA, Lanier LL. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006 320 : re1.
270. Turnbull IR, Colonna M. Activating and inhibitory functions of DAP12. Nat Rev Immunol 2007 7 : 155 161.
271. Barrow AD, Trowsdale J. You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 2006 36 : 1646 1653.
272. Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol 2007 28 : 66 73.
273. Hill JA, et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 2007 27 : 786 800.